Reply to correspondence on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial".
作者信息
Kanzaki Hiroaki, Hoshida Yujin
机构信息
Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
出版信息
Clin Mol Hepatol. 2025 Jan;31(1):e121-e122. doi: 10.3350/cmh.2024.0886. Epub 2024 Oct 11.
Abstract
摘要
相似文献
1
Reply to correspondence on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial".对关于“预测肝细胞癌患者对阿替利珠单抗联合贝伐单抗免疫治疗反应的基因组生物标志物：来自IMbrave150试验的见解”的通信的回复
Clin Mol Hepatol. 2025 Jan;31(1):e121-e122. doi: 10.3350/cmh.2024.0886. Epub 2024 Oct 11.
2
Transcriptomic signature in advanced hepatocellular carcinoma tissue to predict combination immunotherapy response: Editorial on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial".预测晚期肝细胞癌组织中联合免疫治疗反应的转录组特征：关于“预测肝细胞癌中阿替利珠单抗联合贝伐单抗免疫治疗反应的基因组生物标志物：来自IMbrave150试验的见解”的社论
Clin Mol Hepatol. 2025 Jan;31(1):308-310. doi: 10.3350/cmh.2024.0726. Epub 2024 Aug 30.
3
Correspondence to editorial 2 on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 trial".致关于“基因组生物标志物预测肝细胞癌中阿替利珠单抗联合贝伐单抗免疫治疗反应：来自IMbrave150试验的见解”的编辑评论2
Clin Mol Hepatol. 2025 Jan;31(1):e84-e86. doi: 10.3350/cmh.2024.0830. Epub 2024 Oct 7.
4
Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial".使用免疫检查点抑制剂治疗肝细胞癌的个性化方法：关于“预测肝细胞癌对阿替利珠单抗联合贝伐单抗免疫治疗反应的基因组生物标志物：来自IMbrave150试验的见解”的社论
Clin Mol Hepatol. 2025 Jan;31(1):311-315. doi: 10.3350/cmh.2024.0739. Epub 2024 Sep 3.
5
Correspondence to editorial 1 on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Trial".致关于“预测肝细胞癌中阿替利珠单抗联合贝伐单抗免疫治疗反应的基因组生物标志物：来自IMbrave150试验的见解”的社论1的信函。
Clin Mol Hepatol. 2025 Jan;31(1):e81-e83. doi: 10.3350/cmh.2024.0829. Epub 2024 Oct 7.
6
Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial.预测肝细胞癌患者对阿替利珠单抗联合贝伐珠单抗免疫治疗反应的基因组生物标志物：来自 IMbrave150 试验的见解。
Clin Mol Hepatol. 2024 Oct;30(4):807-823. doi: 10.3350/cmh.2024.0333. Epub 2024 Jul 23.
7
Evaluating the cost-effectiveness of atezolizumab-bevacizumab in advanced hepatocellular carcinoma: Insights from Taiwan.评估阿替利珠单抗联合贝伐珠单抗治疗晚期肝细胞癌的成本效益：来自台湾的见解。
J Food Drug Anal. 2025 Jun 13;33(2):163-171. doi: 10.38212/2224-6614.3542.
8
Correspondence to letter to the editor on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial".致编辑的信：关于“预测肝细胞癌中阿替利珠单抗联合贝伐单抗免疫治疗反应的基因组生物标志物：来自IMbrave150试验的见解”的通信
Clin Mol Hepatol. 2025 Jan;31(1):e110-e112. doi: 10.3350/cmh.2024.0828. Epub 2024 Oct 2.
9
Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial.阿替利珠单抗联合化疗加或不加贝伐单抗治疗晚期胆管癌：随机II期IMbrave151试验的临床和生物标志物数据
J Clin Oncol. 2025 Feb 10;43(5):545-557. doi: 10.1200/JCO.24.00337. Epub 2024 Oct 18.
10
Machine learning based radiomic models outperform clinical biomarkers in predicting outcomes after immunotherapy for hepatocellular carcinoma.基于机器学习的放射组学模型在预测肝细胞癌免疫治疗后的预后方面优于临床生物标志物。
J Hepatol. 2025 Apr 17. doi: 10.1016/j.jhep.2025.04.017.
本文引用的文献
1
Correspondence to editorial 1 on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Trial".致关于“预测肝细胞癌中阿替利珠单抗联合贝伐单抗免疫治疗反应的基因组生物标志物：来自IMbrave150试验的见解”的社论1的信函。
Clin Mol Hepatol. 2025 Jan;31(1):e81-e83. doi: 10.3350/cmh.2024.0829. Epub 2024 Oct 7.
2
Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial.预测肝细胞癌患者对阿替利珠单抗联合贝伐珠单抗免疫治疗反应的基因组生物标志物：来自 IMbrave150 试验的见解。
Clin Mol Hepatol. 2024 Oct;30(4):807-823. doi: 10.3350/cmh.2024.0333. Epub 2024 Jul 23.
3
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update.晚期肝细胞癌的系统治疗：ASCO 指南更新。
J Clin Oncol. 2024 May 20;42(15):1830-1850. doi: 10.1200/JCO.23.02745. Epub 2024 Mar 19.
4
Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations.免疫疗法联合治疗方法：机制、生物标志物和临床观察。
Nat Rev Immunol. 2024 Jun;24(6):399-416. doi: 10.1038/s41577-023-00973-8. Epub 2023 Dec 6.
5
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study.基于人工智能的病理学作为肝癌患者对阿替利珠单抗联合贝伐珠单抗敏感性的生物标志物：一项多中心回顾性研究。
Lancet Oncol. 2023 Dec;24(12):1411-1422. doi: 10.1016/S1470-2045(23)00468-0. Epub 2023 Nov 8.
6
Molecular and immune landscape of hepatocellular carcinoma to guide therapeutic decision-making.肝细胞癌的分子和免疫格局以指导治疗决策。
Hepatology. 2025 Mar 1;81(3):1038-1057. doi: 10.1097/HEP.0000000000000513. Epub 2023 Jun 12.
7
Risk stratification and early detection biomarkers for precision HCC screening.肝癌精准筛查的风险分层和早期检测生物标志物。
Hepatology. 2023 Jul 1;78(1):319-362. doi: 10.1002/hep.32779. Epub 2022 Oct 11.
8
Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers.与癌症中抗CTLA-4治疗潜在反应相关的基因组图谱。
Nat Commun. 2017 Oct 19;8(1):1050. doi: 10.1038/s41467-017-01018-0.
Zotero 插件